Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

Safety of NovoMix® 30 (Biphasic Insulin Aspart) Treatment in Patients With Type 2 Diabetes

This study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in patients with type 2 diabetes during NovoMix® 30 treatment.

Inclusion Criteria:

• Any patient with diabetes type 2 diabetes
• Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin
• Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient

Exclusion Criteria:

• Known or suspected allergy to study product(s) or related products
• Pregnancy, breast-feeding or intention of becoming pregnant within the next 6 months